ONI Named a 2026 Trailblazer by WIRED and HSBC UK

FOR IMMEDIATE RELEASE

ONI selected among a prestigious group of pioneering companies recognized for driving innovation, growth, and positive change in health and life sciences.

SAN DIEGO, CA and OXFORD, UK, September 16, 2026

ONI, a leader in super-resolution imaging and advanced biological analysis, has been named a 2026 Health Trailblazer, joining a select group of innovative companies recognized through the Trailblazers Programme, delivered in partnership with WIRED and HSBC UK.

The Trailblazers Program celebrates ambitious, high-growth businesses that are driving innovation, delivering growth, and spearheading positive change within the health sector. ONI was selected as one of this year’s Health & Life Sciences Trailblazers in recognition of the company’s work to transform how researchers see and understand biology at the nanoscale.

At the heart of ONI’s mission is a simple idea: when scientists can see biology more clearly, they can understand it more deeply. That understanding can reveal new insights into disease, accelerate the development of better medicines, and ultimately contribute to better outcomes for patients.

ONI is helping make that possible by combining super-resolution imaging, advanced instrumentation, and AI-powered analysis to enable scientists to observe molecular and cellular processes with unprecedented detail. By making cutting-edge spatial and single-molecule biology more accessible, ONI is giving researchers new ways to ask and answer some of the most important questions in biology and medicine. The Trailblazers materials similarly position ONI’s technology as supporting discovery across fundamental research, drug development, and precision medicine.

“We built ONI around a bold idea: that seeing biology more clearly can change what science is capable of,” said Paul Scagnetti, CEO of ONI. “Today, we’re turning that idea into technology that helps researchers uncover new insights at the molecular level and translate them into meaningful scientific and therapeutic advances. This recognition is a testament to the ambition of our team, the strength of our technology, and the opportunity ahead of us. We’re incredibly proud to be named a 2026 Trailblazer and to help shape what comes next for science.”

Today, ONI joins fellow 2026 Health Trailblazers, WIRED, HSBC UK, and healthcare industry leaders at a celebratory event in London. The gathering brings together this year’s Trailblazers to exchange ideas and insights on innovation and scaling the next generation of health businesses.

The recognition comes at a pivotal time for ONI as the company continues to expand the capabilities and accessibility of super-resolution imaging. By enabling researchers to investigate biology at the molecular level and translate those observations into meaningful insights, ONI aims to help shorten the distance between scientific discovery and real-world impact.

About ONI 
ONI is a private life sciences tools company that transforms therapeutic discovery with accessible, high-performance super-resolution microscopy.  Its backers include ARCH Venture Partners, Casdin Capital and Oxford Science Enterprises (OSE). The company’s first product, the Nanoimager, introduced the world’s first desktop platform for single-molecule imaging, offering 15 nm resolution to study individual molecules in living cells, tissue, and nanoparticles. ONI’s latest innovation, the Aplo Scope, is a compact, end-to-end imaging platform that delivers unmatched clarity, precision, and speed. Designed to empower researchers, the Aplo Scope provides real-time insights into complex biological systems, enabling breakthroughs in drug delivery, biomarker discovery, and antibody therapeutics. For more information, visit oni.bio. Follow ONI @oniHQ and LinkedIn. 

For media inquiries, please contact: 
Carolyn Hartmann 
Director of Product Marketing, ONI 
chartmann@oni.bio